Literature DB >> 6842343

Veno-occlusive disease of the liver associated with cysteamine treatment of nephropathic cystinosis.

E D Avner, D Ellis, R Jaffe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842343     DOI: 10.1016/s0022-3476(83)80261-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  7 in total

1.  Cystinosis as a cause of noncirrhotic portal hypertension.

Authors:  Simona Rossi; Steven K Herrine; Victor J Navarro
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 2.  Update on nephropathic cystinosis.

Authors:  J A Schneider; B Katz; R B Melles
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

3.  Metabolism of pantethine in cystinosis.

Authors:  C T Wittwer; W A Gahl; J D Butler; M Zatz; J G Thoene
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 4.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

5.  Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.

Authors:  Michael R Bendel-Stenzel; Julia Steinke; Ranjan Dohil; Youngki Kim
Journal:  Pediatr Nephrol       Date:  2007-08-01       Impact factor: 3.714

6.  Complications of nephropathic cystinosis after renal failure.

Authors:  W A Gahl; M I Kaiser-Kupfer
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

Review 7.  Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.

Authors:  Fanni Tóth; Edina Katalin Cseh; László Vécsei
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.